1) ENSEMBLE – MA30143: An Open-Label, Single-arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
Date: 2017-Ongoing
PI: Dr. Samia Khoury (previously Dr. Bassem Yamout)
2) CONSONANCE-MN39159: An open-label, single-arm, 4-year study to evaluate the effectiveness and safety of ocrelizumab treatment in patients with progressive multiple sclerosis.
Date: 2019-Ongoing
PI: Dr. Samia Khoury (previously Dr. Bassem Yamout)
3) COMB157G23101: A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy.
Date: 2021-Ongoing
PI: Dr. Samia Khoury
4) WA40404 O'Hand: A phase III b multicenter, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with primary progressive multiple sclerosis.
Date: 2022- Not initiated yet
PI: Dr. Samia Khoury
5) CLOU064C12301: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
PI: Dr. Samia Khoury
Date: Submitted to the IRB Sep 2022, still under review
6) P3-IMU-838-RMS-01 (ENSURE-1): A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Date: Not submitted to the IRB yet – still in negotiation phase
7) SBS-2018-0498: Interacting with Nature using virtual reality: A pilot intervention to restore cognitive fatigue in patients with Multiple Sclerosis (MS)
Date: 2019-Ongoing
PI: Dr. Samia Khoury
8) BIO-2017-0395: Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients: A Single-Blind Randomized Clinical Trial
Date: 2018-Ongoing
PI: Dr. Samia Khoury
9) SBS-2021-0430: The Arabic Validation of the Multiple Sclerosis Resiliency Scale on a Lebanese Sample
Date: 2022- Ongoing
PI: Dr. Samia Khoury
10) IM.SK1.01: Comprehensive Multiple Sclerosis Database.
Date: 2012 – Ongoing
PI: Dr. Samia Khoury
11) IM.SK1.02: Immunological Pattern during Multiple Sclerosis Relapses and Response to Treatment.
Date: 2012 – Ongoing
PI: Dr. Samia Khoury
12) IM.SK1.03: Exosomal microRNAs in Multiple Sclerosis: Reconciling Expression Signatures with Disease Relapse, Remission, and Response to Treatment.
Date: 2015 – Ongoing
PI: Dr. Samia Khoury
13) IM.SK1.05: Cerebrospinal Fluid, Urinary and Plasma Biomarkers in Multiple Sclerosis.
Date: 2012 – Ongoing
PI: Dr. Samia Khoury
14) IM.SK1.06: Development of immunological assays for Multiple Sclerosis.
Date: 2013 – Ongoing
PI: Dr. Samia Khoury
15) IM.SK1.07: Correlation of retinal optical coherence tomography findings with cognitive function in patients with multiple sclerosis.
Date: 2014 – Ongoing
PI: Dr. Samia Khoury
16) IM.SK1.08: EBV Infected B Lymphocyte Exosomes and Dendritic Cells:
Differential Cytokine Profile in Multiple Sclerosis.
Date: 2014 – Ongoing
PI: Dr. Samia Khoury
17) IM.SK1.09: Clinical Usefulness of Visual, Somatosensory, and Brainstem Auditory Evoked Potentials for Monitoring of Disease Activity and Management in Multiple Sclerosis.
Date: 2015 – Ongoing
PI: Dr. Samia Khoury
18) 109MS311: A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis.
Date: 2016 – 2018 – Closed
PI: Dr. Bassem Yamout
19) EFC11759: A two year, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis followed by an open-label extension.
Date: 2014 – 2022 Closed
PI: Dr. Bassem Yamout
20) CFTY720D2404: The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis.
Date: 2013 – Ongoing
PI: Dr. Bassem Yamout
21) IM.BY.10: Multiple Sclerosis Patient Registry:
Date: 2015 – Ongoing
Dr. Bassem Yamout
22) IM.BY.11: Efficacy and Safety of Cyclophosphamide Treatment in Progressive Multiple Sclerosis: The Clinical Experience of the AUBMC Multiple Sclerosis Center in Lebanon.
Date: 2015 – Ongoing
Dr. Bassem Yamout
23) MS200136_0035: A Multicenter, prospective, non-interventional study to assess Adherence to treatment for patients with Relapsing Multiple Sclerosis (RMS) who are prescribed subcutaneous (sc) interferon beta-1a.
Date: 2017 – 2021
Dr. Bassem Yamout
24) TERIFR07918: Longitudinal assessment of clinical disability, cognition, quality of life, fatigue, brain magnetic resonance imaging measures, and optical coherence tomography findings in multiple sclerosis patients treated with AUBAGIO® (teriflunomide).
Date: 2016 – 2017
Dr. Bassem Yamout
25) BICAMS: Brief International Cognitive Assessment for MS (BICAMS)-Arabic
Date: 2016 – closed
PI: Dr. Hala Darwish
26) IM.SK1.04: Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients.
Date: 2012-2017
PI: Dr. Samia Khoury
27) 109MS202: : Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years.
Date: 2015 – 2016
28) CP-NU100-01.00: A phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of NU100 in Patients with Relapsing Forms of Multiple Sclerosis.
Date: 2012 – 2012
PI: Dr. Bassem Yamout
29) 28981: Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif® New Formulation (REFLEXION).
Date: Ended
PI: Dr. Bassem Yamout
30) EMR200559-006: A Phase III, Randomized, Double-Blind, Double-Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO-4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 μg IM Weekly in Subjects with Relapsing-Remitting Multiple Sclerosis.
Date: 2014 – 2014
PI: Dr. Bassem Yamout
31) EMR7008568-012: Prospective Observational Long-Term Safety Registry of Multiple Sclerosis Patients who have participated in Cladribine Clinical Trials (PREMIERE).
Date: 2015 – 2017
PI: Dr. Bassem Yamout
32) IM.BY.07: Efficacy and safety of Fingolimod treatment in Multiple Sclerosis: The clinical experience of the AUBMC Multiple Sclerosis Center in Lebanon.
Date: 2014 - 2016
PI: Dr. Bassem Yamout
33) IM.BY.08: The Rate of Anti-JC Virus Antibody Seroconversion in the Middle East: A multi-Center Analysis.
Date: 2014 – 2015
PI: Dr. Bassem Yamout
34) IM.BY.09: Incidence and Diagnostic Predictors of Mimickers of Multiple Sclerosis in a Specialized Referral Center in Lebanon.
Date: 2015 – 2017
PI: Dr. Bassem Yamout
35) IM.BY.12: Safety and Efficacy of Natalizumab in Multiple Sclerosis: Real World Evidence in the Middle East
Date: 2016 – 2017
PI: Dr. Bassem Yamout
36) Modulation of Th17 Differentiation and Survival by Vitamin D Via the Wnt/-catenin Pathway.
Date: 2015 – 2017
PI: Dr. Bassem Yamout
37) The EBV Seropositivity, Vitamin D Level and Smoking Rate among Multiple Sclerosis patients compared to Healthy Individuals in Lebanon .
Date: 2012 - 2017
PI: Dr. Bassem Yamout